Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Biosimilar Neulasta In Final Stages Of EMA Review Process

Executive Summary

A biosimilar version of Amgen’s Neulasta has yet to be approved in the EU but one such product is in the later stages of review at the European Medicines Agency.

You may also be interested in...



EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic

EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.

EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic

EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.

Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

Rolontis, a novel, long-acting granulocyte colony-stimulating factor (G-CSF) licensed out to Spectrum Pharmaceuticals, has become Hanmi Pharmaceuticals' first drug developed with its proprietary platform to approach the regulatory filings stage in global markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel